The EU Health Technology Assessment (HTA) Regulation, effective January 2025 for oncology and advanced therapy medicinal products (ATMPs), aims to improve access to innovative therapies by providing reliable and transparent information for healthcare decision-making. Despite advances, disparities in access to cancer treatments persist across the EU due to varying HTA methodologies. The new regulation seeks to address these differences and reduce fragmentation across the EU by providing reliable and transparent information to support decision-making in healthcare policy and practice at both national and European levels.
CPE is committed to inform and promote patient involvement in HTA. For that purpose, it is actively engaged as a member of the EU’s HTA Multistakeholder Network and has produced, published and disseminated responses to the European Commission’s consultations on its implementing acts to its members. CPE is also organising different actions to raise awareness among the cancer patient community on the importance of HTA for their life and wellbeing and the crucial role they can play in HTA processes.
If you would like to learn more, click on the following relevant links.
- Health Technology Assessment – Joint clinical assessment of medicinal products
- Health Technology Assessment – Procedural rules for assessing and managing conflicts of interest
- Health Technology Assessment – Cooperation with the European Medicines Agency
- Concerned Stakeholders Issue Call to Action on the Clinical Assessment for ATMPs
- 10 Key Recommendations for Enhancing Joint Clinical Assessments Under the EU HTA Regulation
- What is the Joint Clinical Assessment (JCA)?
Related News
At Cancer Patients Europe our vision is to reduce the burden of cancer on patients and survivors, their carers, the healthcare system and society as a whole. We achieve this by giving patients voice in policies that drive prevention, high quality cancer care, treatment and survivorship in Europe.
Our policy work includes anticipating, providing advice and contributing to the formulation of relevant legislative proposals taking place at the European level. Our activities on policy include the publication of Calls to Action, position papers, input on consultations by the European Commission, the European Medicines Agency and direct engagement with policymakers.
Learn more about our policy work as we continue to push for a brighter future for the cancer community.